Maria Pia Sormani

Maria Pia Sormani

Top Cited Scholar 2026
Auto-generated profile, based on publicly available information

Maria Pia Sormani

Department of Health Sciences, University of Genoa, Genova, Italy

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2014 in Neurology
Verified
Journal Article
Open access
PDF file
FLFred D. Lublin
Fred D. Lublin
SRStephen C. Reingold
Stephen C. Reingold
JCJeffrey A. Cohen
Jeffrey A. Cohen
GCGary R. Cutter
Gary R. Cutter
PSPer Soelberg Sørensen
Per Soelberg Sørensen
CPChris H. Polman
Chris H. Polman
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment of clinical trials, and treatment decision-making. Standardized descriptions published in 1996 based on a survey of international MS experts provided purely clinical phenotypes based on data and consensus at that time, but imaging and biological correlates were lacking. Increased understanding of MS and its pathology, coupled with general concern that the original descriptors may not adequately reflect more recently identified clinical aspects of the disease, prompted a re-examination of MS disease phenotypes by the International Advisory Committee on Clinical Trials of MS. While imaging and biological markers that might provide objective criteria for separating clinical phenotypes are lacking, we propose refined descriptors that include consideration of disease activity (based on clinical relapse rate and imaging findings) and disease progression. Strategies for future research to better define phenotypes are also outlined.

31 August 2018 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
MKMichael Khalil
Michael Khalil
CTCharlotte E. Teunissen
Charlotte E. Teunissen
MOMarkus Otto
Markus Otto
FPFredrik Piehl
Fredrik Piehl
MSMaria Pia Sormani
Maria Pia Sormani
JKJens Kuhle
Jens Kuhle

20 January 2018 in Multiple Sclerosis Journal
Verified
Journal Article
Open access
XMXavier Montalban
Xavier Montalban
RGRalf Gold
Ralf Gold
ATAlan J Thompson
Alan J Thompson
SOSusana Otero-Romero
Susana Otero-Romero
MAMaria Pia Amato
Maria Pia Amato
FZFrauke Zipp
Frauke Zipp
Background: Multiple sclerosis (MS) is a complex disease with new drugs becoming available in the past years. There is a need for a reference tool compiling current data to aid professionals in treatment decisions. Objectives: To develop an evidence-based clinical practice guideline for the pharmacological treatment of people with MS. Methods: This guideline has been developed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and following the updated EAN recommendations. Clinical questions were formulated in Patients–Intervention–Comparator–Outcome (PICO) format and outcomes were prioritized. The quality of evidence was rated into four categories according to the risk of bias. The recommendations with assigned strength (strong and weak) were formulated based on the quality of evidence and the risk-benefit balance. Consensus between the panelists was reached by use of the modified nominal group technique. Results: A total of 10 questions were agreed, encompassing treatment efficacy, response criteria, strategies to address suboptimal response and safety concerns and treatment strategies in MS and pregnancy. The guideline takes into account all disease-modifying drugs approved by the European Medicine Agency (EMA) at the time of publication. A total of 21 recommendations were agreed by the guideline working group after three rounds of consensus. Conclusion: The present guideline will enable homogeneity of treatment decisions across Europe.

1 August 2019 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
MGMarco Gattorno
Marco Gattorno
MHMichael Hofer
Michael Hofer
SFSilvia Federici
Silvia Federici
FVFederica Vanoni
Federica Vanoni
FBFrancesca Bovis
Francesca Bovis
NRNicolino Ruperto
Nicolino Ruperto
Background Different diagnostic and classification criteria are available for hereditary recurrent fevers (HRF)—familial Mediterranean fever (FMF), tumour necrosis factor receptor-associated periodic fever syndrome (TRAPS), mevalonate kinase deficiency (MKD) and cryopyrin-associated periodic syndromes (CAPS)—and for the non-hereditary, periodic fever, aphthosis, pharyngitis and adenitis (PFAPA). We aimed to develop and validate new evidence-based classification criteria for HRF/PFAPA. Methods Step 1: selection of clinical, laboratory and genetic candidate variables; step 2: classification of 360 random patients from the Eurofever Registry by a panel of 25 clinicians and 8 geneticists blinded to patients’ diagnosis (consensus ≥80%); step 3: statistical analysis for the selection of the best candidate classification criteria; step 4: nominal group technique consensus conference with 33 panellists for the discussion and selection of the final classification criteria; step 5: cross-sectional validation of the novel criteria. Results The panellists achieved consensus to classify 281 of 360 (78%) patients (32 CAPS, 36 FMF, 56 MKD, 37 PFAPA, 39 TRAPS, 81 undefined recurrent fever). Consensus was reached for two sets of criteria for each HRF, one including genetic and clinical variables, the other with clinical variables only, plus new criteria for PFAPA. The four HRF criteria demonstrated sensitivity of 0.94–1 and specificity of 0.95–1; for PFAPA, criteria sensitivity and specificity were 0.97 and 0.93, respectively. Validation of these criteria in an independent data set of 1018 patients shows a high accuracy (from 0.81 to 0.98). Conclusion Eurofever proposes a novel set of validated classification criteria for HRF and PFAPA with high sensitivity and specificity.

12 April 2024 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
MKMichael Khalil
Michael Khalil
CTCharlotte E. Teunissen
Charlotte E. Teunissen
SLSylvain Lehmann
Sylvain Lehmann
MOMarkus Otto
Markus Otto
FPFredrik Piehl
Fredrik Piehl
JKJens Kuhle
Jens Kuhle

15 September 2015 in Nature Reviews Neurology
Verified
Journal Article
Open access
PDF file
OGon behalf of the MAGNIMS study group
on behalf of the MAGNIMS study group
MWMike P. Wattjes
Mike P. Wattjes
ÀRÀlex Rovira
Àlex Rovira
DMDavid Miller
David Miller
TYTarek A. Yousry
Tarek A. Yousry
XMXavier Montalban
Xavier Montalban
The role of MRI in the assessment of multiple sclerosis (MS) goes far beyond the diagnostic process. MRI techniques can be used as regular monitoring to help stage patients with MS and measure disease progression. MRI can also be used to measure lesion burden, thus providing useful information for the prediction of long-term disability. With the introduction of a new generation of immunomodulatory and/or immunosuppressive drugs for the treatment of MS, MRI also makes an important contribution to the monitoring of treatment, and can be used to determine baseline tissue damage and detect subsequent repair. This use of MRI can help predict treatment response and assess the efficacy and safety of new therapies. In the second part of the MAGNIMS (Magnetic Resonance Imaging in MS) network's guidelines on the use of MRI in MS, we focus on the implementation of this technique in prognostic and monitoring tasks. We present recommendations on how and when to use MRI for disease monitoring, and discuss some promising MRI approaches that may be introduced into clinical practice in the near future.